Home » Stocks » Verastem

Verastem, Inc. (VSTM)

Stock Price: $1.28 USD -0.03 (-2.29%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $1.29 +0.01 (0.78%) Oct 19, 5:25 PM

Stock Price Chart

Key Info

Market Cap 217.00M
Revenue (ttm) 22.01M
Net Income (ttm) -129.91M
Shares Out 169.53M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $1.28
Previous Close $1.31
Change ($) -0.03
Change (%) -2.29%
Day's Open 1.32
Day's Range 1.27 - 1.33
Day's Volume 1,164,161
52-Week Range 0.83 - 4.67

More Stats

Market Cap 217.00M
Enterprise Value 115.77M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 169.53M
Float 159.80M
EPS (basic) -1.41
EPS (diluted) -1.23
FCF / Share -0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 10.07M
Short Ratio 2.85
Short % of Float 6.30%
Beta 0.72
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.86
PB Ratio 1.94
Revenue 22.01M
Operating Income -108.33M
Net Income -129.91M
Free Cash Flow -121.65M
Net Cash 101.24M
Net Cash / Share 0.60
Gross Margin 73.68%
Operating Margin -492.17%
Profit Margin -590.20%
FCF Margin -552.69%
ROA -31.54%
ROE -158.74%
ROIC -106.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
(212.50% upside)
Low
3.00
Current: $1.28
High
5.00
Target: 4.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue17.4626.72-------
Revenue Growth-34.67%--------
Gross Profit14.6526.13-------
Operating Income-132-94.78-67.80-37.00-58.20-53.61-41.40-32.23-13.70
Net Income-149-72.43-67.80-36.44-57.87-53.37-41.20-31.98-13.68
Shares Outstanding74.5864.9638.4236.9935.9325.8022.6818.771.30
Earnings Per Share-2.00-1.37-1.76-0.99-1.61-2.07-1.82-1.70-10.59
Operating Cash Flow-139-74.52-57.31-29.48-45.56-36.90-26.31-22.60-9.37
Capital Expenditures-0.01-23.43--0.04-0.21-2.43-0.06-0.31-0.79
Free Cash Flow-139-97.94-57.31-29.52-45.77-39.33-26.36-22.91-10.16
Cash & Equivalents11125086.6781.0611092.8810156.6647.90
Total Debt10812014.83------
Net Cash / Debt3.7212971.8481.0611092.8810156.6647.90
Assets14527789.7983.6311398.6512592.9259.04
Liabilities13815332.1111.3310.639.887.822.4671.80
Book Value7.1712457.6872.3010288.7711790.47-12.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Verastem, Inc.
Country United States
Employees 135
CEO Brian M. Stuglik

Stock Information

Ticker Symbol VSTM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VSTM
IPO Date January 27, 2012

Description

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Company and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.